BioTime to Webcast Presentation at the Ladenburg Thalmann 2016 Healthcare Conference
September 23 2016 - 7:00AM
Business Wire
BioTime, Inc. (NYSE MKT:BTX), a clinical stage regenerative
medicine company with a focus on pluripotent stem cell technology,
today announced that it will be presenting at the Ladenburg
Thalmann 2016 Healthcare Conference in New York City on Tuesday,
September 27, 2016, at 1:00 p.m. Eastern Time / 10:00 a.m. Pacific
Time.
The Ladenburg Thalmann Healthcare Conference is a well-respected
event for investors who are specifically focused on healthcare and
life sciences companies such as BioTime. This venue allows
BioTime’s management to provide a corporate overview and update on
its product development.
Attendance is by invitation only. However, the presentation will
be webcast live and will also be available for replay at the
“Events & Presentations” page of the “Investors & Media”
section on BioTime’s website at http://www.biotimeinc.com/.
About BioTime
BioTime, Inc. is a clinical-stage biotechnology company focused
on developing and commercializing novel therapies developed from
what we believe to be the world’s premier collection of pluripotent
cell assets. The foundation of our core therapeutic technology
platform is pluripotent cells that are capable of becoming any of
the cell types in the human body. Pluripotent cells have potential
application in many areas of medicine with large unmet patient
needs, including various age-related degenerative diseases and
degenerative conditions for which there presently are no cures.
Unlike pharmaceuticals that require a molecular target, therapeutic
strategies based on the use of pluripotent cells are generally
aimed at regenerating or replacing affected cells and tissues, and
therefore may have broader applicability than pharmaceutical
products.
In addition to the development of therapeutics, BioTime’s
research and other activities have resulted, over time, in the
creation of other subsidiaries that address other non-therapeutic
market opportunities such as cancer diagnostics, drug development
and cell research products, and mobile health software
applications.
BioTime common stock is traded on the NYSE MKT and TASE under
the symbol BTX. For more information, please visit
www.biotimeinc.com or connect with the company on Twitter,
LinkedIn, Facebook, YouTube, and Google+.
To receive ongoing BioTime corporate communications, please
click on the following link to join our email alert list:
http://news.biotimeinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160923005182/en/
BioTime, Inc.Dan L. Lawrence,
510-775-0510dlawrence@biotimeinc.comorInvestor Contact:EVC Group,
Inc.Michael Polyviou, 646-445-4800mpolyviou@evcgroup.comorMedia
Contact:Gotham Communications, LLCBill Douglass,
646-504-0890bill@gothamcomm.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024